By Nicholas Jasinski | Tuesday, July 28
Afternoon Swoon. Stocks dropped into the closing bell today, after
spending most of the session just below the break-even line. No fewer than 21 S&P 500 components reported second-quarter results after
today's close, with another 14 on deck to report before the market reopens
tomorrow. And the dribs and drabs of intelligence about congressional
wrangling over a trillion-dollar stimulus package continue to emerge.
Either or both could mean a volatile open for the
market tomorrow, and seemed to be motivation for traders to not hold
stocks overnight. Hence the last-hour drop in stocks.
The S&P 500 closed down 0.6%, the Dow
Jones Industrial Average fell
0.8%, and the Nasdaq Composite dropped 1.3%.
Contrary to yesterday's tech-led rally, today's action
had a decidedly defensive tilt to it. Real estate and utilities were the
best performing sectors in the S&P 500, while materials and energy were the
laggards. Tech shares gave back some of their gains from yesterday. And
safe-haven assets rose, with gold finishing up 0.7% at another record high—its
fourth straight.
The morning's earnings reports got most of the attention
today, with news on most of the macro forces driving the market largely
incremental.
Coronavirus case growth in the U.S. has eased over the
past week, as hot spots in a number of states appear to have turned a corner.
Reimposed lockdown measures are having an effect, but cases are still rising in
most of the country.
This morning's consumer
confidence index for July from the Conference
Board also
reflected those actions. The index slipped to 92.6, from June’s upwardly
revised 98.3. The consensus estimate had been for a 95.5 reading. It wasn’t a
huge month-over-month drop, but nonetheless showed that rising coronavirus
cases across the U.S. have had an impact on household sentiment.
High-profile
results this morning came from McDonald's, 3M, Pfizer, Raytheon Technologies, Harley-Davidson, Altria Group, and more. After the bell, Starbucks, eBay, Advanced Micro Devices, and Amgen added their second-quarter reports.
No comments:
Post a Comment